Price variation among different brands of anticancer medicines available in hospital pharmacies of Nepal

To assess the variation in price among different brands of anticancer medicines available in hospital pharmacies at Nepalese cancer hospitals. The price of different brands of the same anticancer medicines available in the hospital pharmacies of two cancer hospitals was assessed. Prices of different...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical policy and practice 2020-04, Vol.13 (1), p.6-6, Article 6
Hauptverfasser: Shrestha, Sunil, Poudel, Ramesh Sharma, Kc, Bhuvan, Poudel, Bhupendra Kumar, Sapkota, Binaya, Sharma, Sabina, Khadka, Anil
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To assess the variation in price among different brands of anticancer medicines available in hospital pharmacies at Nepalese cancer hospitals. The price of different brands of the same anticancer medicines available in the hospital pharmacies of two cancer hospitals was assessed. Prices of different dosage forms such as a single tablet, capsule and vial were calculated. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical industries was determined, and the percentage variation in price was calculated. The prices of medicines (brands) were also compared with the price determined by the government where available. Price variation was assessed for 31 anticancer medicines belonging to six broad categories. Prices were found to vary maximally among the following medicines, each belonging to separate categories: among alkylating agents, the price of temozolomide 100 mg capsule varied 308%; among antimetabolite agents, the price of pemetrexed 500 mg injection varied 134%; among hormonal drugs, the price of letrozole 2.5 mg tablet varied 200%; among antibody class, the price of trastuzumab 440 mg injection varied 73%; among natural products, the price of irinotecan 100 mg injection varied 590%; and among miscellaneous agents, the price of bortezomib 2 mg injection varied 241%. There was a significant difference in the mean MRP of the alkylating agents with the antimetabolites ( -value 0.006) and the monoclonal antibody ( -value
ISSN:2052-3211
2052-3211
DOI:10.1186/s40545-020-0203-0